Search research articles
Contact Us
Filters
Showing results (491-500 of 515) with videos related to
Page
of 52
Sort By:
Pulmonary Pharmacology
|
January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig
D W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma
M C Chabot-Fletcher, D C Underwood, J J Breton, et al.
Cancer Research
|
March 14, 2012
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100
Juliet Richards, Ai Chiin Lim, Colin W Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
D C Underwood, R R Osborn, C J Kotzer, et al.
Genes and Immunity
|
October 26, 2007
Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populations
G Zhu, K Carlsen, K-H Carlsen, et al.
Journal of Medicinal Chemistry
|
March 26, 1999
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)
G A Giardina, L F Raveglia, M Grugni, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist
H M Sarau, D E Griswold, W Potts, et al.
The Journal of Physiology
|
October 31, 2019
Postnatal β2 adrenergic treatment improves insulin sensitivity in lambs with IUGR but not persistent defects in pancreatic islets or skeletal muscle
Dustin T Yates, Leticia E Camacho, Amy C Kelly, et al.
European Journal of Pharmacology
|
February 28, 2001
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor
H M Sarau, J A Feild, R S Ames, et al.
The Journal of Endocrinology
|
January 6, 2017
Myoblast replication is reduced in the IUGR fetus despite maintained proliferative capacity in vitro
Susan M Soto, Amy C Blake, Stephanie R Wesolowski, et al.
Page
of 52
Search research articles
Search
Showing results (491-500 of 515) with videos related to
Sort By:
Page
of 52
Pulmonary Pharmacology
|
January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig
D W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma
M C Chabot-Fletcher, D C Underwood, J J Breton, et al.
Cancer Research
|
March 14, 2012
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100
Juliet Richards, Ai Chiin Lim, Colin W Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
D C Underwood, R R Osborn, C J Kotzer, et al.
Genes and Immunity
|
October 26, 2007
Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populations
G Zhu, K Carlsen, K-H Carlsen, et al.
Journal of Medicinal Chemistry
|
March 26, 1999
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)
G A Giardina, L F Raveglia, M Grugni, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist
H M Sarau, D E Griswold, W Potts, et al.
The Journal of Physiology
|
October 31, 2019
Postnatal β2 adrenergic treatment improves insulin sensitivity in lambs with IUGR but not persistent defects in pancreatic islets or skeletal muscle
Dustin T Yates, Leticia E Camacho, Amy C Kelly, et al.
European Journal of Pharmacology
|
February 28, 2001
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor
H M Sarau, J A Feild, R S Ames, et al.
The Journal of Endocrinology
|
January 6, 2017
Myoblast replication is reduced in the IUGR fetus despite maintained proliferative capacity in vitro
Susan M Soto, Amy C Blake, Stephanie R Wesolowski, et al.
Page
of 52